

AUTHOR INDEX

Abboud, C.N., 31
Abrams, S.I., 118
Ahlgren, J.D., 241
Allay, J.A., 46
Alter, C.A., 229
Althausen, A.F., 614
Arca, M.J., 108
Bales, G.T., 605
Bane, B.L., 546
Baron, P.L., 714, 719
Belair, C.D., 571
Belli, J., 292
Berd, D., 4, 22
Berd, D., 773
Bleloch, R.H., 571
Bonadonna, G., 413, 464
Bookstein, R., 66
Brennan, M.F., 352
Calabretta, B., 78
Cannon-Albright, L.A., 667
Chak, A., 336
Chang, A.E., 108
Chatterjee, S., 159
Chen, S.Y., 148
Cole, D.J., 719, 754
Conlon, K.C., 347
Conry, R.M., 135
Cooper, M.J., 172
Curiel, D.T., 135
Cuthill, S., 571
Davis, B.M., 46
De Potter, P., 763, 768
Demers, W., 66
Dhingra, K., 436
Donoso, L.A., 768
Douglas, R.M., 614
Driscoll, M.S., 734
Eisenlohr, L.A., 88
El Kassas, H., 737
Elder, D., 682
Elwood, J.M., 650
Fenoglio-Preiser, C.M., 292
Fisher, B., 414
Freeman, J.L., 31
Freeman, S.M., 31
Fukushima, M., 369
Fusaro, L.R., 251
Fusaro, R.M., 251
Garrison, M., 725
Gattoni-Celli, S., 754
Gelber, R.D., 494
Gerson, S.L., 1, 46
Gerwitz, A.M., 78
Ghadirian, P., 251
Gilboa, E., 101
Goldhirsch, A., 494
Grant-Kels, J.M., 734
Gregory, R., 66
Grin, C.M., 734
Halaban, R., 673
Halvorsen, R.A.Jr., 325
Hand, P.H., 118
Harris, J.R., 453
Hart, I.R., 154
Hayek, M., 281
Hemstreet, G.P., 546
Henderson, I.C., 506
Heney, N.M., 614
Hortobagyi, G.N., 436
Howe, G., 281
Hrubian, R.H., 251
Hudis, C.A., 475
Huebner, K., 22
Jenrette, J.M., 759
Jones, P.A., 536
Kamb, A., 667
Karpesh, M.S.Jr., 347, 352
Katai, H., 360
Kaufman, D.S., 614
Keller, J.M., 693
Kelsen, D.P., 279, 379
Kenady, D.E., 200
Kern, S.E., 251
Kim, H., 605
Kinoshita, T., 360
Kirwood, J.M., 737
Kmiec, E.B., 188
Koc, O.N., 46
Kryger, J.V., 585
Lamm, D.L., 598
Lattime, E.C., 1, 4, 88
Lee, K., 46
Lee, S.S., 88
Lemon, S.J., 251
Lightdale, C.J., 251
LoBuglio, A.F., 135
Lu, D., 159
Lubinski, J., 22
Lynch, H.T., 251
Lynch, J.F., 251
Macdonald, J.S., 199, 220
Maguire, H.C.Jr., 22, 773
Maize, J.C., 693
Manevel, D., 66
Marasco, W.A., 148
Marrogi, A.J., 31
Mastrangelo, M.J., 4, 88, 773
McCarthy, W.H., 709
McClay, E.F., 649, 744
McClay, M.E.T., 744
McCormick, V.D., 325
McGrath, P.C., 200
Meruyama, K., 360
Messing, E., 585
Metcalf, J.S., 688
Minsky, B.D., 390
Mule, J.J., 108
Nathan, F., 773
Nathan, F.E., 4
Nathanson, L., 725
Neugut, A.I., 281
Nixon, A., 453
Noffsinger, A.E., 292
Norton, L., 475
Nseyo, U.O., 598
Ohta, M., 22
Page, D.L., 428
Park, J., 66
Pollack, B.J., 336
Puthenveetil, J.A., 571
Rao, J.Y., 546
Ratajczak, M.Z., 78
Reese, J.S., 46
Reznikoff, C.A., 571
Rivers, J.K., 709
Ross, R.K., 536
Roth, B.J., 633
Sagabiel, R.W., 703
Sano, T., 360
Sasako, M., 360
Sato, T., 773
Savelieva, E., 571
Scher, H.I., 535
Schlom, J., 118
Schnall, S.F., 220
Schwartz, G.K., 316
Semba, S., 307
Seykora, J., 682
Shaughenessy, E., 159
Shaw, H.M., 709
Shields, C.L., 763, 768
Shields, J.A., 763, 768
Shipley, W.U., 614
Simpson, J.F., 428
Singh, A.D., 763, 768
Sivak, M.V.Jr., 336
Skolnick, M., 667
Skorski, T., 78
Sloan, D.A., 200
Smith, G., 506
Smyrk, T., 251

AUTHOR INDEX

Abboud, C.N., 31
Abrams, S.I., 118
Ahlgren, J.D., 241
Allay, J.A., 46
Alter, C.A., 229
Althausen, A.F., 614
Arca, M.J., 108
Bales, G.T., 605
Bane, B.L., 546
Baron, P.L., 714, 719
Belair, C.D., 571
Belli, J., 292
Berd, D., 4, 22
Berd, D., 773
Bleloch, R.H., 571
Bonadonna, G., 413, 464
Bookstein, R., 66
Brennan, M.F., 352
Calabretta, B., 78
Cannon-Albright, L.A., 667
Chak, A., 336
Chang, A.E., 108
Chatterjee, S., 159
Chen, S.Y., 148
Cole, D.J., 719, 754
Conlon, K.C., 347
Conry, R.M., 135
Cooper, M.J., 172
Curiel, D.T., 135
Cuthill, S., 571
Davis, B.M., 46
De Potter, P., 763, 768
Demers, W., 66
Dhingra, K., 436
Donoso, L.A., 768
Douglas, R.M., 614
Driscoll, M.S., 734
Eisenlohr, L.A., 88
El Kassas, H., 737
Elder, D., 682
Elwood, J.M., 650
Fenoglio-Preiser, C.M., 292
Fisher, B., 414
Freeman, J.L., 31
Freeman, S.M., 31
Fukushima, M., 369
Fusaro, L.R., 251
Fusaro, R.M., 251
Garrison, M., 725
Gattoni-Celli, S., 754
Gelber, R.D., 494
Gerson, S.L., 1, 46
Gerwitz, A.M., 78
Ghadirian, P., 251
Gilboa, E., 101
Goldhirsch, A., 494
Grant-Kels, J.M., 734
Gregory, R., 66
Grin, C.M., 734
Halaban, R., 673
Halvorsen, R.A.Jr., 325
Hand, P.H., 118
Harris, J.R., 453
Hart, I.R., 154
Hayek, M., 281
Hemstreet, G.P., 546
Henderson, I.C., 506
Heney, N.M., 614
Hortobagyi, G.N., 436
Howe, G., 281
Hrubian, R.H., 251
Hudis, C.A., 475
Huebner, K., 22
Jenrette, J.M., 759
Jones, P.A., 536
Kamb, A., 667
Karpesh, M.S.Jr., 347, 352
Katai, H., 360
Kaufman, D.S., 614
Keller, J.M., 693
Kelsen, D.P., 279, 379
Kenady, D.E., 200
Kern, S.E., 251
Kim, H., 605
Kinoshita, T., 360
Kirwood, J.M., 737
Kmiec, E.B., 188
Koc, O.N., 46
Kryger, J.V., 585
Lamm, D.L., 598
Lattime, E.C., 1, 4, 88
Lee, K., 46
Lee, S.S., 88
Lemon, S.J., 251
Lightdale, C.J., 251
LoBuglio, A.F., 135
Lu, D., 159
Lubinski, J., 22
Lynch, H.T., 251
Lynch, J.F., 251
Macdonald, J.S., 199, 220
Maguire, H.C.Jr., 22, 773
Maize, J.C., 693
Manevel, D., 66
Marasco, W.A., 148
Marrogi, A.J., 31
Mastrangelo, M.J., 4, 88, 773
McCarthy, W.H., 709
McClay, E.F., 649, 744
McClay, M.E.T., 744
McCormick, V.D., 325
McGrath, P.C., 200
Meruyama, K., 360
Messing, E., 585
Metcalf, J.S., 688
Minsky, B.D., 390
Mule, J.J., 108
Nathan, F., 773
Nathan, F.E., 4
Nathanson, L., 725
Neugut, A.I., 281
Nixon, A., 453
Noffsinger, A.E., 292
Norton, L., 475
Nseyo, U.O., 598
Ohta, M., 22
Page, D.L., 428
Park, J., 66
Pollack, B.J., 336
Puthenveetil, J.A., 571
Rao, J.Y., 546
Ratajczak, M.Z., 78
Reese, J.S., 46
Reznikoff, C.A., 571
Rivers, J.K., 709
Ross, R.K., 536
Roth, B.J., 633
Sagabiel, R.W., 703
Sano, T., 360
Sasako, M., 360
Sato, T., 773
Savelieva, E., 571
Scher, H.I., 535
Schlom, J., 118
Schnall, S.F., 220
Schwartz, G.K., 316
Semba, S., 307
Seykora, J., 682
Shaughenessy, E., 159
Shaw, H.M., 709
Shields, C.L., 763, 768
Shields, J.A., 763, 768
Shipley, W.U., 614
Simpson, J.F., 428
Singh, A.D., 763, 768
Sivak, M.V.Jr., 336
Skolnick, M., 667
Skorski, T., 78
Sloan, D.A., 200
Smith, G., 506
Smyrk, T., 251

Stadler, W., 533
 Steinberg, G.D., 605
 Stemmermann, G.M., 292
 Sternberg, C.N., 621
 Tahara, E., 307
 Tahara, H., 307
 Thomas, P.R.M., 213
 Thompson, J.F., 709

Troyan, S., 453
 Tsang, K.Y., 118
 Valagussa, P., 464
 Vogelzang, N., 533
 Wang, M.X., 768
 Whartenby, K.A., 31
 Wills, K., 66

Wils, J., 397
 Wong, K.K., 159
 Wood, W.C., 446
 Yeager, T.R., 571
 Yee, J., 325
 Yiu, M.C., 536
 Zietman, A.L., 614

SUBJECT INDEX

Aminobiphenyl
 exposure to, bladder cancer risk of, 537
 hemoglobin adduct level of, 540

AB2, 777

Abelson leukemia virus, 34

ABL, functional classification of, 6

Acetaminophen, in pancreatic cancer, 234

Aclarinomycin, as single-agent chemotherapy, in pancreatic cancer, 221

ACN53 therapy, clinical studies of, 72

Acral lentiginous melanoma
 characterization of, 705
 epidemiology of, 705
 plantar variant of, 706
 subungual variant of, 705-706
 therapeutic implications in, 706

Actin, in tumor cell invasion, 319

Active specific immunization
 adjunctive, randomized trials of, 774
 antigen supplemented tumor cell vaccines in, 776
 cyclophosphamide immunopotentiation of, 774-775
 with defined immunogens, 777
 in melanoma, 773-781

Adeno-associated virus, 11
 for gene therapy, 160-161

Adenocarcinoma
 of pancreas, 220-228
 of stomach, *see* Gastric cancer

Adenomatous polyposis coli, 264

Adenomatous polyposis coli gene, in gastric cancer, 309

Adenoviral vector, 55
 for p53 gene delivery, 68-70

Adenovirus, generating recombinant, 69

Adjuvant therapy
 evolution of, in breast cancer, 418-420
 guiding principles of, 476
 in gastric cancer, 379-389
 patient selection for, 380-381
 postoperative, timing of, 381
 postoperative regimens for, 381
 prognostic factor guideline for, 442
 radiotherapy plus, in pancreatic cancer, 214
 recurrence following, 476-478
 selection of, 482-483

Adoptive cellular therapy
 genetic approaches to, 108-117

Adoptive cellular therapy (Continued)
 history of, 108-109

Adrenalectomy
 in breast cancer, 497
 mechanism of action of, 496

Adriamycin, *see* Doxorubicin

Age
 breast-conserving therapy and, 457-458
 chemotherapy and, 482
 gastric cancer incidence by, 282
 for females, 285
 for males, 285
 in melanoma, 728

Agency for Health Care Policy and Research, pain guidelines of, 232

Alcohol, familial pancreatic cancer and, 252

Aldehyde dehydrogenase, 49-50

Allogeneic bone marrow transplantation, HSV-TK in, 40

Alpha FGF oncogene, in bladder cancer, 578

Alpha-catenin, in gastric cancer, 309-310

Alpha-interferon, fluorouracil, cisplatin regimen, in bladder cancer, 640

Alpha-tocopherol, gastric cancer and, 285-287

American Joint Committee Cancer staging, of melanoma, 729-730

Amines, aromatic, as bladder cancer risk, 589

Aminoglutethimide, 501, 519

Amplification, oncogene activation by, 28-29

Amsacrine, as single-agent chemotherapy, in pancreatic cancer, 221

Analgesia
 patient controlled, 235-236
 side effects of, 236-237

Analgesics, as bladder cancer risk factor, 539-540

Androgens
 in breast cancer, 498
 mechanism of action of, 496

Anemia, pernicious, familial pancreatic cancer and, 259-260

Angiogenesis
 animal tumor modeling of, 465
 in breast cancer, 439

Aniline, exposure to, bladder cancer risk of, 537

Anthracenediones, 515-516

Anthracycline agents, in pancreatic cancer, 222

Anti-ras effector mechanism, 121-122

Antiandrogens, 502
 mechanism of action of, 496

Antibody-T cell receptor complex, chimeric, 114

Antiestrogens
 mechanism of action of, 496
 without estrogenic activity, 499-500

Antifolates, 516-517

Antigen(s)
 gene transfer, 17
 melanoma differentiation, 755-756
 melanoma-associated tumor, 755
 17-1A, 16
 tumor, autoreactivity and, 756-757

Antigen-presenting cell, 755, 89

Antiprogestins, 502
 mechanism of action of, 496

Antisense therapy, 13

Antisense transcript, 164-165

Antitumor immunity, modulation of, 166-167

Antrum, gastric cancer in, 293

APC, tumors associated with, 8

Apoptosis
 characterization of, 34
 chimeric molecule and, 191
 in gastric cancer, 311

ARA-C, *see* Cytarabine

Arnidex, 520

Aromatase inhibitors, 500-501
 mechanism of action of, in breast cancer, 496

Arsenic, exposure to, bladder cancer risk of, 539-540

Arylamine(s)
 -induced bladder cancer pathogenesis, 538
 exposure to, bladder cancer risk of, 537

Ascorbate, gastric cancer and, 285-287

Aspirin, in pancreatic cancer, 234

Autocrine growth, 675

Autocrine growth loop, 246

Autocrine motility factor, in tumor cell invasion, 319

Autoreactivity, tumor antigen and, 756-757

Axillary dissection
 for ductal carcinoma in situ, 451
 need for, 459
 optimal extent of, 459
 survival following, 458-459

AZQ, as single-agent chemotherapy, in pancreatic cancer, 221

B7, 89-91

B7-CD28, 17

Bacillus Calmette-Guerin
 bladder cancer recurrence and, 600
 in bladder cancer, 599-601
 complications of, 601
 injection of, 88-89
 vaccine, autologous whole tumor cell plus, with cyclophosphamide, 773-775

Balloon cell, 691

BCL-2 gene
 functional classification of, 6
 targets for, 192

BCNU, *see* Carmustine

BCR-ABL transcript, targeting of, 79

Benzidine, exposure to, bladder cancer risk of, 573

Beta carotene, gastric cancer and, 286-287

Beta-catenin, in gastric cancer, 309-310

Beta-glucosidase, 33

Beta-lactamase, 33

Betulinic acid, in metastatic melanoma, 745-746

Biliary drainage, preoperative, 203

Biliary-enteric bypass, 208

Biologic therapy, in pancreatic cancer, 225

Biological response modifier, in gastric cancer, 373-374

Biomarker(s)
 biological, for screening, in bladder cancer, 594
 classification of, 561
 for screening, 564-565
 for therapy selection, 566
 general concepts of, 562
 in bladder cancer, 560-561
 of tumor progression, 567
 risk category profile of, 561
 selection of, for clinical evaluation, 562-563

Biopsy
 CT-guided transmural core, 559
 excisional, of nevus, 715
 indications for, in melanoma, 714
 strip, 341
 technique for
 in melanoma, 714-715
 in pancreatic cancer, 202
 transvesical needle, 559

Biphosphonates, 522

Bisantrene, in bladder cancer, 634

Bladder, *see* Urinary bladder

Bladder cancer
 advanced
 chemotherapy in, 633-644
 staging of, radiologic methods for, 555
 anthracenediones in, 634
 anthracyclines in, 634
 antrifol in, 636
 artificial sweetners and, 539
Bacillus Calmette-Guerin immunotherapy in, 599-601
 biology of, 629
 biomarkers in, 560-561
 bisantrene in, 634
 characteristics of, 571-573
 chemotherapy in, cost benefit analysis of, 629
 chromosomal changes associated with, 542
 chromosome regions lost or gained in, 573-574
 cigarette smoking and, 537-539
 cisplatin in, 633-634
 clinical staging of, 553-555
 diagnostic tests for, 560-561
 cisplatin, methotrexate, vinblastine regimen in, 638
 cisplatin, cyclophosphamide, doxorubicin regimen in, 637-638
 cisplatin, methotrexate regimen in, 636-637
 coffee drinking and, 539
 combination chemotherapy in, 615, 636-640
 combined modality therapy in, 615
 combined neoadjuvant and adjuvant chemotherapy in, 629
 cyclophosphamide in, 635

Bladder cancer (*Continued*)
demographics of, 536-537
diagnosis of, 553-555
docetaxel in, 635
doxorubicin in, 634
epidemiological risk factors in, 537-540
epidemiology of, 536-545
epirubicin in, 634
escalated methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 639
ethnic groupings in, 537
etoposide in, 635
evaluation of, 553-555
field cancerization in, 562
field disease in, 562
fluorouracil, alpha-interferon, cisplatin regimen in, 640
gallium nitrate, fluorouracil regimen in, 640
gallium nitrate in, 636
gemcitabine in, 636
general histological considerations in, 546
genetic alterations in, 573-577
 clinical relevance of, 580
genetics of, critical questions in, 573
hematuria in, for screening, 590-593
histopathology of, 542
hyperplasia in, 546-547
ifosfamide in, 635
incidence of, 585, 598, 621-622
interferon in, 601-602
intra-arterial methotrexate, doxorubicin, cisplatin regimen in, 624
intra-arterial neoadjuvant chemotherapy in, 624
intravesical therapy in, 599
 indications for, 598-599
Jewett-Strong-Marshal classification of, 552
locally advanced, 621-632
 adjuvant chemotherapy in, 627-629
 neoadjuvant chemotherapy in, 622-624
 surgical therapy for, 605-613
metaplasia in, 546-547
metastatic
 combination chemotherapy in, 622
 radiographic staging of, 555-556
methotrexate in, 634
methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 638-639
mitoxantrone in, 634
multimodality bladder preservation in, 611
muscle-invading
 chemoradiation in, 614-620
 conservative surgery in, 614-620
muscle-invasive, 559-560
natural history of, 587-589
occupational exposures in, 537
oncogenes activated in, 578
overview of, 533-534
oxazaphosphorines in, 635
p53 alterations in, 576
paclitaxel in, 635
pathogenesis of, 536-545
 cytogenetic studies of, 542-543
Bladder cancer (*Continued*)
molecular genetic model of, 571-584
molecular studies of, 543
pathological considerations in, 546
pathological staging in, 559
pathology of, 546-570
photofrin-mediated photodynamic therapy in, 602
pirarubicin in, 634
pirtrexim in, 636
podophyllotoxin derivatives in, 635
possible protective factors in, 540
pRb alterations in, 576
premalignant urothelial lesions of, 546-547
prognostic factors in, 629
progression of, proposed model for, 539
race in, 537
RB alterations in, 576
risk factors for, 589
screening for, 585-597
 appropriateness of, 589-590
 cost-effectiveness of, 593
 cytology in, 593-594
 in high-risk populations, 594-595
 molecular biological markers in, 594
single-agent chemotherapy in, 633-636
smoking-related carcinogens in, metabolism alterations of, 540-542
staging of, 546-570
 transvesical needle biopsy for, 559
superficial, therapy of, 598-604
survival in, 573
taxanes in, 635
teniposide in, 635
therapy in, average cost of, 629
TP53 alterations in, 576
transurethral resection in, pathological evaluation of, 556-559
trimetrexate in, 636
tumor suppressor genes associated with, 542
variants of, 551
vinblastine, ifosfamide, gallium nitrate regimen in, 640
vinblastine in, 634
vinca alkaloids in, 634-635
vincristine in, 634-635
vinorelbine in, 635
Blue nevus, 696-697
 cellular, melanoma in, 706-707
Bone marrow, micrometastasis of, in breast cancer, 439-440
Bone marrow transplantation
 allogenic, 40
 with chemotherapy, 487-488
Bone scan, in advanced bladder cancer staging, 555
Borrmann classification, of gastric cancer, 298
Boyden chamber, 317, 318
BRCA1, tumors associated with, 8
BRCA2, tumors associated with, 8
Breast cancer
 adjuvant therapy guidelines in, 442
 angiogenesis in, 439
 breast conservation in, see Breast-conserving treatment
 cathepsin D in, 439

Breast cancer (*Continued*)

- chemotherapy in, predicting efficacy of, 440-441
- current therapy of, 422
- endocrine therapies in, 441, 494-505
- growth regulators in, 438-439
- introduction to, 413
- invasive
 - cell proliferation in, 432-433
 - chemoradiotherapy sequencing for, 460
 - chemotherapy *v* surgery for, 471-472
 - colloid type of, 432
 - ductal, see Ductal carcinoma *in situ*
 - extensive intraductal neoplasia in, 455
 - grading in, 430-431
 - grading utility in, 431
 - histologic typing in, 431-432
 - histological grading in, 431
 - histopathology of, 430
 - infiltrating lobular, 432
 - lobular, 446-452
 - local management of, 453-463
 - medullary, 432
 - mucinous, 432
 - pleomorphic lobular, 432
 - prognostic factors in, 433
 - prognostication in, 430-433
 - staging in, 430
 - subset analysis in, 431
 - surgical timing for, 459-460
 - tubular type of, 431-432
 - wide excision surgery for, 460
- ipsilateral recurrence of, clinical trials and, 417-418
- kinetic model in, 488-489
- margin evaluation in, 455-456
- mastectomy in, 422
- micrometastases in, 436-440
- molecular markers in, 437-440
- morphologic markers in, 436-440
- neu overexpression in, 438
- new treatments for, 506-528
- nonrandomized trials in, 467-468
- operable
 - adjuvant drug therapy for, 475-493
 - primary chemotherapy in, 464-474
 - risk assessment in, 483-484
- palliative therapy of, 521-523
- plasminogen activator inhibitor in, 439
- premalignancy in, 428-435
- prevention of, tamoxifen for, 423-424
- prognostic factors in, 429, 437
- prognostic markers in, 421-422, 441
- proteases in, 438-439
- randomized trials in, 466
- research progress in, 414-427
- urokinase-type plasminogen activator in, 439

Breast-conserving treatment, 453-454

- contraindications to, 456-457
- cosmetic results of, 458
- mastectomy *v*, 454
- patient selection for, 454-457
- selection of, 457-458

Brunn's nests, 547, 551

Buserelin, 497, 502, 520

Bystander effect, 34

- in vivo mechanism of action of, 36-38

C-erbB-2, in breast cancer, 429, 433

C-met gene, in gastric cancer, 311-312

C-MYB transcript, targeting of, 79-81

C-myc, in breast cancer, 438

CA 19-9, in pancreatic cancer, 203

Cadherins, in tumor cell invasion, 319

Canji adenovirus construct, 70-71

Capsid, definiton of, 6

Carcinoembryonic antigen immunization, 136-137

- dosing of, 137-138
- plasmid, 138
- route of, 138-139

Carcinogenesis, multistep, 562

Cardia

- cancer incidence in, 282-284, 286
- gastric cancer in, 293

Carmofur, as single-agent chemotherapy, in pancreatic cancer, 221

Carmustine, 222

- in combination chemotherapy, for pancreatic cancer, 223-224
- in metastatic melanoma, 745

Carmustine, dacarbazine, cisplatin, tamoxifen regimen, in metastatic melanoma, 746-748

Carmustine, dacarbazine, cisplatin, tamoxifen, interferon- α regimen, in metastatic melanoma, 750

Carmustine, dacarbazine, cisplatin, tamoxifen, interleukin-2, interferon regimen, in metastatic melanoma, 750

Carmustine, dacarbazine, megestrol, cisplatin regimen, in metastatic melanoma, 749

Cathepsin, in tumor cell invasion, 319

Cathepsin-B, 320

Cathepsin-D, in breast cancer, 439

Cathepsin-L, 320

Catheter probe, 342

Cationic lipid-mediated gene transfer, 73-74

CCNU, see Lomustine

CD, 33, 39-40

CD28 receptor, 17

CD4+

- human anti-ras, T-cell line, cytokine production by, 130
- human anti-ras Val 12, T-cell line, cytotoxic activity by, 130
- murine anti-ras, T cell responses, 122, 123, 125-127
- T cell response, from normal individuals, 129-130

CD8+

- human, cytotoxic T-lymphocyte responses, to point-mutated ras, 130-131
- murine anti-ras, T cell responses, 122, 123, 127-129

CD44, in gastric cancer, 312

CDKN2 gene, 27, 543

- MLM and, 669-770
- CDKN2-p16, 577-580

CEA, see Carcinoembryonic antigen

Celiac plexus block, 237-238

Cell cycle, regulators of, 676-677

Cell proliferation, in breast cancer, 432-433
Charcoal, in gastric cancer, 375-376
Chemical exposure, pancreatic cancer and, 245
Chemohormonal therapy, trials of, 480
Chemoimmunotherapy
 in gastric cancer, 373-374
 in metastatic melanoma, 750-751
Chemoradiotherapy
 in muscle-invading bladder cancer, 614-620
 organ-preserving, results following, 618
 in postoperative adjuvant regimens, for gastric cancer, 383
 sequencing of, for invasive breast cancer, 460
Chemotherapy
 adjuvant
 advantages of, 627
 clinical trials of, 627-629
 disadvantages of, 627
 in bladder cancer, 627-629
 age and, 482
 anthracenedione, in bladder cancer, 634
 anthracycline, in bladder cancer, 634
 antifol, in bladder cancer, 636
 biomarkers for, 566
 combination, *see* Combination chemotherapy
 combined neoadjuvant and adjuvant, in bladder cancer, 629
 evolution of, in breast cancer, 418-420
 FDA-approved, 507
 genetic engineering facilitating, 13-19
 hematologic tolerance enhancement of, 13-14
 intra-arterial neoadjuvant, in bladder cancer, 624
 intraperitoneal, for gastric cancer, 384-385
 intravesical, in bladder cancer, 599
 Japanese adjuvant, 369-372
 liposomal delivery of, 517-518
 in metastatic melanoma, 746-750
 neoadjuvant
 bladder preservation and, 625
 for gastric cancer, 385-386
 in locally advanced bladder cancer, 622-624
 in locally advanced gastric cancer, 403
 oxazaphosphorine, in bladder cancer, 635
 in pancreatic cancer, 267-268
 perioperative intraperitoneal, 374-376
 podophyllotoxin derivative, in bladder cancer, 635
 predicting efficacy of, in breast cancer, 440-441
 preoperative
 in breast cancer, 420-422
 intraperitoneal, 374-376
 lumpectomy plus, 420-422
 primary
 animal tumor modeling for, 464-464
 clinical trials of, 465-468
 in operable breast cancer, 464-474
 scope of, 465
 randomized trials of, for advanced gastric cancer, 400-401
 regimens of, in breast cancer, 481-482
 remodeling of, in breast cancer, 420-422
 supportive care *v.* in advanced gastric cancer, 401-402
 surgically placed adjuvants for, 356-357
 taxane, in bladder cancer, 635
 in uveal melanoma, 766

Chemotherapy (Continued)
 vinca alkaloid, in bladder cancer, 634-635
Chimeric molecule, apoptosis and, 191
Chlorambucil, as single agent, in metastatic breast cancer, 523
Cholangiography, percutaneous, in pancreatic cancer, 201-202
Cholangiopancreatography, endoscopic, 265-266
 in pancreatic cancer, 201-202
Cholecystoenterostomy, reoperation following, 208
Cholecystostomy, 200
Cholecystojejunostomy, 200
Choledochoenterostomy, reoperation following, 208
Chromosome, regions of, lost or gained, in bladder cancer, 573-574
Chromosome 1, dysplastic nevus syndrome-melanoma susceptibility and, 668
Chromosome 3p, deletions of, in clear cell renal cell cancer, 24-25
Chromosome 9, loss at, 577-578
 homozygous deletions at, in melanoma cell line, 26
 melanoma susceptibility and, 668-669
Cigarette smoking
 as bladder cancer risk, 537, 589
 gastric cancer and, 288
 pancreatic cancer and, 243-244
Cisplatin
 in bladder cancer, 633-634, 637-638
 in combination chemotherapy
 for advanced gastric cancer, 398-399
 for bladder cancer, 615, 622
 for pancreatic cancer, 223
 in combined modality therapy, for bladder cancer, 615
 in gastric cancer, 374-376
 in metastatic bladder cancer, 622
 postoperative adjuvant, 381
Cisplatin, cyclosporine, doxorubicin regimen
 in bladder cancer, 637-638
 in metastatic bladder cancer, 622
Cisplatin, dacarbazine, carbustine, megestrol regimen, in metastatic melanoma, 749
Cisplatin, dacarbazine, carbustine, tamoxifen regimen, in metastatic melanoma, 746-748
Cisplatin, dacarbazine, carbustine, tamoxifen, interferon-alfa regimen, in metastatic melanoma, 750
Cisplatin, dacarbazine, carbustine, tamoxifen, IL-2, interferon regimen, in metastatic melanoma, 750
Cisplatin, dacarbazine, tamoxifen regimen, in metastatic melanoma, 749
Cisplatin, dacarbazine, tamoxifen, IL-2 regimen, in metastatic melanoma, 750
Cisplatin, fluorouracil, alpha-interferon regimen, in bladder cancer, 640
Cisplatin, methotrexate regimen, in bladder cancer, 636-637
Cisplatin, methotrexate, doxorubicin regimen, intra-arterial, in bladder cancer, 624
Cisplatin, methotrexate, vinblastine regimen, in bladder cancer, 638
Cisplatin, tamoxifen regimen, in metastatic melanoma, 748-749
Cisplatin, vinblastine, dacarbazine, IL-2, interferon-alfa regimen, in metastatic melanoma, 750
Clark classification, 725
Clark's nevus, 695-696

Clodronate, 522

Clonal nevus, 699-700

Cockayne's syndrome, 50

Codeine

- for moderate to severe pain, 235
- in pancreatic cancer, 234

Coffee

- bladder cancer risk of, 539
- familial pancreatic cancer and, 252

Collagenase

- interstitial, 319
- type IV, 319, 320

Colloid carcinoma, of breast, 432

Colorectal cancer

- hereditary nonpolyposis, familial pancreatic cancer and, 260
- oncogenesis in, 9-10
- p53 abnormalities in, 66-67
- p53 gene therapy in, 66-77

Combination chemotherapy

- in bladder cancer, 636-640
- common, 223
- cost of, 629
- in metastatic bladder cancer, 622
- in pancreatic cancer, 222-224

Combined modality therapy

- evolution of, 615-616
- in uveal melanoma, 766
- results of, 616-618

Combined nevus, 699-700

Comparative genomic hybridization, 573

Computed tomography

- abdominal, 201
- in advanced bladder cancer staging, 555-556
- in gastric cancer, 327-332
- in gastric cancer staging, 330-332
- of gastric anatomy, 329-330
- in pancreatic cancer, 265
- technique of, in gastric cancer, 328-329
- transmural core biopsy guided by, 559

Constipation, following opioids, 236-237

Contrast agents, for MRI, in gastric cancer, 332-333

Corpus, gastric, cancer in, 293

Cost-effectiveness

- of bladder cancer screening, 593
- of gastric cancer detection, 325
- of radical cystectomy, 629

Costimulatory signal, 754-755

CT, *see* Computed tomography

Cyclin D1, 677

Cyclin-dependent kinase, 675-676

- in gastric cancer, 310-311

Cyclin-dependent kinase inhibitor, 675

Cyclin-dependent kinase-4 inhibitor gene, in uveal melanoma, 770

Cyclines, in gastric cancer, 310-311

Cyclophosphamide

- for immunopotentiation, of active specific immunization, 774-775
- in bladder cancer, 635, 637-638
- in breast cancer, 419, 481-482
- in breast cancer therapy, 468-470

Cyclophosphamide (Continued)

- in metastatic bladder cancer, 622
- oral, in combination chemotherapy, 482
- overview of, 484-485
- as single agent, in metastatic breast cancer, 523

Cyclophosphamide, doxorubicin regimen, in breast cancer, 419-420, 422

CYP1A2, 540

CYP2C19, 540

CYP2D6, 540

CYP3A4, 540

Cystectomy

- partial, 610-611
- bladder preservation and, 625
- radical
- cost of, 629
- in bladder cancer, 605-606
- sexual function following, 607
- specimen of, 549
- salvage, 611-612

Cystitis cystica, 547

Cystoprostatectomy, radical, specimen of, 549

Cystoscopy, 626

Cytarabine

- in pancreatic cancer, 225
- postoperative adjuvant, in gastric cancer, 381

Cytokine deaminase, 33

Cytokine gene transfer, 16-17

- in situ*, 93-97
- recombinant vaccinia virus, 96
- studies of, 92-93
- with vaccinia virus vectors, 88-100

Cytology, fine needle aspiration, endoscopic ultrasonography in, 342-343

Dacarbazine, in metastatic melanoma, 744

Dacarbazine, carmustine, cisplatin, tamoxifen regimen, in metastatic melanoma, 746-748

Dacarbazine, carmustine, cisplatin, tamoxifen, interferon-alfa regimen, in metastatic melanoma, 750

Dacarbazine, carmustine, cisplatin, tamoxifen, interleukin-2, interferon regimen, in metastatic melanoma, 750

Dacarbazine, carmustine, megestrol, cisplatin regimen, in metastatic melanoma, 749

Dacarbazine, cisplatin, tamoxifen regimen, in metastatic melanoma, 749

Dacarbazine, cisplatin, tamoxifen, IL-2 regimen, in metastatic melanoma, 750

Dacarbazine, cisplatin, vinblastine, IL-2, interferon-alfa regimen, in metastatic melanoma, 750

Dacarbazine, fotemustine regimen, in metastatic melanoma, 750

Dacarbazine, tamoxifen regimen, in metastatic melanoma, 749

DCC, tumors associated with, 8

DEOD, 33

Depressive disorders, in pancreatic cancer, 229-230

Dermal melanocytosis, 768-769

Desmoplastic neurotrophic melanoma, 705

Developmental gene, characteristics of, 8

DHAD, as single-agent chemotherapy, in pancreatic cancer, 221

Diabetes
 familial pancreatic cancer and, 257-259
 pancreatic cancer and, 246-247

Dichloromethylene bisphosphonate, 522

Dietary carcinogens
 gastric cancer and, 284-287
 pancreatic cancer and, 243-244

Dihydrofolate reductase, 440, 516, 48
 in drug resistance gene transfer, 55-56

Dinitrophenyl, 776

DNA
 chemical modification sites in, 85
 direct injection of, 174-175
 precipitated, with calcium phosphate, 176
 vaccine, 105

DNA conjugate, ligand, 177-178

DNA exceeding rate, 5C, 564-565

DNA ploidy analysis, in transitional cell carcinoma, 564-565

Do Not Resuscitate order, 238-239

Docetaxel, 506, 510-511
 in bladder cancer, 635
 in breast cancer, 489
 in metastatic melanoma, 745
 in pancreatic cancer, 225
 phase II trials of, 511
 as single agent, in metastatic breast cancer, 523

Dominant-negative hypothesis, of p53, 68

Dose-density, of chemotherapy, in breast cancer, 488-489

Dosing, optimal, of chemotherapy, 481

Douglas cavity, 375

Doxil, 517

Doxorubicin
 in bladder cancer, 634, 637-638
 in breast cancer, 469
 in combination chemotherapy, 223, 481
 for bladder cancer, 615
 in combined modality therapy, for bladder cancer, 615
 liposomal delivery of, 517-518
 in metastatic bladder cancer, 622
 methotrexate, cisplatin regimen, intra-arterial, in bladder cancer, 624
 overview of, in breast cancer, 485-487
 in pancreatic cancer, 214
 postoperative adjuvant, 381
 in postoperative adjuvant regimens, 383
 preoperative, 470
 as single-agent chemotherapy, 221
 in metastatic breast cancer, 523

Doxorubicin, cyclophosphamide regimen, in breast cancer, 419-420, 422

Doxorubicin, vinblastine, thiotepa, fluoxymesterone regimen, in breast cancer, 486

Droloxitene, 521
 in breast cancer, 499

Drug resistance gene
 clinical trials of, 56-59
 mechanisms of, 47-52
 retroviral transduction of, 53
 transfer of, 46-65

DU-PAN-2, 203

Ductal carcinoma in situ
 atypical ductal hyperplasia v, 429
 axillary dissection for, 451
 biopsy for, 448-449
 classification of, 430
 current therapy of, 422-423
 definition of, 448
 excision alone for, 449-451
 excision plus radiation for, 449
 histopathology of, 429
 management of, 446-452
 mastectomy for, 450
 natural history of, 447-448
 randomized studies of, 450
 surgery for, 449-451
 therapeutic algorithms for, 450-451
 treatment options for, 449-451

Dye, chemical, as bladder cancer risk factor, 589

Dysplastic nevus(i)
 as cancer precursor, 683
 as cancer risk marker, 683
 as cancer simulant, 683
 clinical features of, 682
 histological features of, 683
 as melanoma epidemiological risk factors, 684-685
 melanoma incidence rates following, 686
 as melanoma risk marker, 682-687
 relative risk estimates for, 685

Dysplastic nevus syndrome, 667-668
 and melanoma susceptibility, chromosome 1 linkage of, 668

counts in, melanoma susceptibility and, 668

E-cadherin
 in gastric cancer, 309-310
 in tumor cell invasion, 319, 320

EF21, 676

Early Breast Cancer Trialists' Collaborative Group, 476-478

Ebstein Barr virus, HSV-TK treatment of, 40

Ecotoposide, as single-agent chemotherapy, in pancreatic cancer, 221

Edatrexate
 phase II activity of, 516
 as single agent, in metastatic breast cancer, 523

EGFr oncogene, in bladder cancer, 578

Elective lymph node dissection
 nonrandomized trials in, results of, 720
 ongoing randomized trials in, 721-722
 prospective trials in, 720-721
 randomized trials in, results of, 720-721
 retrospective trials in, 720
 theoretical considerations in, 719-720

Endocrine therapy
 in breast cancer, 494-505
 resistance to, 495
 response to, 495

Endoscopic retrograde cholangiopancreatography, 265-266
 in pancreatic cancer, 201-202

Endoscopic ultrasonography
 CT v, in gastric cancer staging, 340-341
 in early gastric cancer, 341-342
 in fine needle aspiration cytology, 342-343

Endoscopic ultrasonography (Continued)
 in gastric cancer, 336-346
 in gastric cancer staging, 337-338
 gastric cancer staging problems with, 341
 gastric cancer survival by, 358
 gastric depth penetration of, 340
 of gastric five-layer wall structure, 337
 instrumentation for, 336-337
 in large gastric folds, 343-344
 in *linitis plastica*, 343-344
 in lymphoma, 343-344
 in Menetrier's disease, 343-344
 in pancreatic cancer, 266-267
 in scirrhouous carcinoma, 343-344

Endoscopy, in gastric cancer detection, 325

Endothelin-1, 673

Endothelin-2, 673

Endothelin-3, 673

Endothelin-B receptor, 674

Enucleation, in uveal melanoma, 765-766

Enzyme system, to target drug effects, 14

Eosinophilic globule, 699

Epidermal growth factor receptor, 518

Epirubicin
 in bladder cancer, 634
 in combination chemotherapy, for bladder cancer, 615
 in combined modality therapy, for bladder cancer, 615
 as single-agent chemotherapy, in pancreatic cancer, 221

Episome, characteristics of, 180-182

Epithelial growth factor, gastric cancer and, 302

erb-B, functional classification of, 6

erbB-2 oncogene, in bladder cancer, 578

Estrogen(s)
 in breast cancer, 498
 mechanism of action of, 496

Ethnic groupings, in bladder cancer, 537

Etoposide
 in bladder cancer, 635
 in breast cancer, 469
 in gastric cancer, 374-376
 postoperative adjuvant, 381

Excision repair cross complementing gene, 50-51

Expression system, plasmid-based, rationale for, 173-174

Fadrazole, 519

tamoxifen *v.*, 520

Familial adenomatous polyposis, familial pancreatic cancer and, 260

Familial atypical mole and melanoma syndrome, 769

Familial atypical multiple mole melanoma syndrome, 682

Familial pancreatic cancer
 alcohol and, 252
 coffee and, 252
 diabetes and, 257-259
 differential genetic diagnosis in, 254-255
 epidemiology of, 251-253
 in extended families, 253-254
 extrapancreatic cancers and, 254
 familial adenomatous polyposis and, 260
 familial pancreatic cancer and, 260-262
 family aggregation in, 253

Familial pancreatic cancer (Continued)
 FAMMM syndrome and, 260-262
 geographic variation in, 251
 hereditary nonpolyposis colorectal cancer and, 260
 hereditary pancreatitis and, 255-257
 nutrition and, 251-252
 pernicious anemia and, 259-260
 population case-control studies in, 252-253
 racial variation in, 251
 tobacco and, 252

Females
 age-specific gastric cancer incidence in, 285
 gastric cancer incidence in, 283

Ferric ammonium citrate, 332

Fibroblast growth factor family, 673-674

Field cancerization, 562

Field disease, 562

Field effect, 716

Fine needle aspiration cytology, endoscopic ultrasonography in, 342-343

Flow cytometric analysis, in breast cancer, 432-433

Flow cytometry, for screening, in bladder cancer, 593-594

Fluorescent dye, as biomarker, 564-565

Fluorescent *in situ* hybridization, 573

Fluorouracil, 517
 in breast cancer, 419, 481-482, 420, 468, 469, 470
 in combination chemotherapy, 223-224
 plus folinic acid, in combination chemotherapy, for advanced gastric cancer, 399-400
 in gastric cancer, 375-376
 infusional, in combination chemotherapy, for advanced gastric cancer, 397-398
 overview of, 484-485
 in pancreatic adenocarcinoma, 220-221
 postoperative adjuvant, in gastric cancer, 381
 as single-agent chemotherapy, 221
 in metastatic breast cancer, 523

Fluorouracil, alpha-interferon, cisplatin regimen, in bladder cancer, 640

Fluorouracil, gallium nitrate regimen, in bladder cancer, 640

Fluoxymesterone, vinblastine, doxorubicin, thiotepa regimen, in breast cancer, 486

Folinic acid, 221
 plus fluorouracil, in combination chemotherapy, for advanced gastric cancer, 399-400

Fondation Bergonie trial, in breast cancer, 466

Fotemustine, in metastatic melanoma, 745

Fotemustine, dacarbazine regimen, in metastatic melanoma, 750

French Cooperative Group trial, in breast cancer, 468

Fruit, gastric cancer and, 287

G-actin, 564-565, 567

G-protein, 673

Gadopentetate dimeglumine, 332

Gallium nitrate, in bladder cancer, 636

Gallium nitrate, fluorouracil regimen, in bladder cancer, 640

Gallium nitrate, vinblastine, ifosfamide regimen, in bladder cancer, 640

Ganciclovir, 32-34, 38-40
 uses of, 40

Ganglioside, 777-778
plus interferon, in melanoma, 741-742

Gastrectomy
pancreas-preserving total, 367
partial, 288
pancreatic cancer following, 246
pylorus-preserving distal, 366
total v subtotal, in antral gastric adenocarcinoma, 354

Gastric cancer
adjuvant therapy for, 379-389
advanced
chemotherapy v supportive care in, 401-402
combination chemotherapy in, 397-401
prognostic factors in, 402-403
radiographic findings in, 326-327
radiotherapy in, 402
treatment of, 397-406
age distribution of, 282
age-specific incidence of, by sex, 285
alpha-tocopherol and, 285-287
analytic epidemiology of, 284-288
anatomic subsite distribution in, 282-284
ascorbate and, 285-287
beta carotene and, 286-287
biological response modifiers in, 373-374
Bormann classification of, 298
c-met gene in, 311-312
cell kinetics in, 301
cell lines in, 309, 317
chemoimmunotherapy in, 373-374
chronic atrophic gastritis and, 287-288
classification of, 296-299
CT of, 327-332
curative resections of, American T and N stage distribution and, 354
cyclin-dependent kinases in, 310-311
cyclines in, 310-311
diagnosis of, 325-327
diet and, 284-287
diffuse type of, development of, 295
early, 295-296, 297
classification of, 297
endoscopic ultrasonography in, 341-342
radiographic findings in, 325-326
endoscopic ultrasonography in, 336-346
endoscopic ultrasonography staging accuracy in, 338-340
endoscopic ultrasonography staging of, 337-338
epidemiology of, 281-291
epithelial growth factors and, 302
failure pattern in, 379-380
fruit and, 287
gastric polyps and, 293-294
gastric ulcers and, 293
gastritis and, 292-293
genes altered in, 308
genetic instability in, 307-309
gross features of, 296
H-2 blockers and, 288
Helicobacter pylori and, 288
hepatocyte growth factor in, 311-312
histological features of, 298

Gastric cancer (Continued)
incidence of, 281, 283
in selected populations, 353
international distribution of, 282
intestinal metaplasia and, 287-288
intestinal type of, 293
invasive, cytoplasmic projections and, 322
Japanese adjuvant therapy for, 369-378
Japanese surgical management of, 360-368
Japanese surgical procedures for, 360-365
laparoscopic staging of, 347-348
laparoscopic ultrasonography in, 349-350
local regional, treatment algorithm for, 387
locally advanced, neoadjuvant chemotherapy in, 403
lymph node dissection in, 355-356
Menetrier's disease and, 294
metastases in, 316-324
CT of, 330
metastasis-related genes in, 312
metastatic signet cell, CT of, 331
microscopic features of, 297-298
molecular biological observations in, 307-315
molecular biology of, 301-302
mortality due to, 282
MRI of, 332-334
mucosal damage and, 287-288
neoadjuvant therapy for, 379-389
nitrites and, 285-287
node-positive, American v Japanese survival in, 357
OK-432 in, 373-374
oncogenes in, 311-312
orthotopic model for, 323
overview of, 279-280
partial gastrectomies and, 288
pathologic considerations in, 281
pathologic features of, 292-306
pathology specimen in, examination of, 302-304
perioperative intraperitoneal chemotherapy in, 374-376
phenotypic features of, 292-306
preoperative intraperitoneal chemotherapy in, 374-376
prognostic factors in, 298-299
progression of, mucosal damage and, 295
protein-bound beta-D-glucan in, 373-374
proximal, American incidence of, 353
race distribution of, 282
radiotherapy in, 390-396
radiotherapy rationale in, 390
randomized trials in, meta-analysis of, 372-373
recurrence of, following surgery, 342
replication errors in, 301-302
risk factors for, 288
salt and, 287
scirrhouous, radiographic findings in, 326-327
sex distribution of, 282
shelf-life proximal margin in, CT of, 331
SK-GT cell lines in, 316, 317
smoking and, 288
spread of, 299-301
staging of, 299-300, 327-334
subtypes of, 293
surgery for, in US, 352-359

Gastric cancer (Continued)
 surgical management of, historical perspective of, 353-354
 surgically placed adjuvants in, 356-357
 survival in, by endoscopic ultrasound, 358
 synchronous multicentric, 296-297
 telomerase activity in, 308
 time trends in, 282, 286
 TNM staging of, 300, 338
 TNM v Japanese classification in, 370
 treatment algorithm for, 351
 treatment of, 353
 tumor cell invasion in, 317
 factors associated with, 319
 tumor doubling time in, 301
 tumor extension and, 361
 tumor suppressor genes and, 301-302
 US age distribution of, 353
 US diagnostic approaches to, 353
 US incidence of, 284, 352-353
 US v Japanese surgical results in, 356
 US surgical management of, 352-359
 US survival rates for, 284
 by T stage, 356
 by TNM stage, 357
 vegetables and, 287
 with lymphoid stroma, 300
 World Health Organization classification of, 298

Gastric emptying, following modified Whipple procedure, 205

Gastric fold, large, endoscopic ultrasonography in, 343-344

Gastric pseudotumor, 329

Gastric resection
 adjacent organ resection with, survival benefit of, 362
 combined, for adjacent structure vertical invasion, 361
 current approaches to, 357-358
 endoscopic mucosal, 365
 extent of, 354
 failure patterns following, 391
 for invisible peritoneal metastasis, 364-365
 for lymph node metastasis, 361-364
 function preserving procedures and, 365-366
 laparoscopic wedge, 366
 margin of, 355
 quality of life following, 365-366
 to remove stomach wall horizontal extention, 360-361
 strategies for, 361
 survival following, 355
 total v subtotal gastrectomy type of, 354-355
 transdiaphragmatic approach in, 362
 US v German v Japanese results of, 361
 US v Japanese results of, 356

Gastritis
 as gastric cancer risk factor, 292-293
 autoimmune, 292
 chronic atrophic, gastric cancer and, 287-288

Gastro-esophageal junction, 329

Gastrointestinal Study Group Trials, in pancreatic cancer, 213-215

Gastrointestinal tract examination, upper, in gastric cancer detection, 325

Gastroscopy, in gastric cancer detection, 325

Gemcitabine
 as single-agent chemotherapy, 221
 in bladder cancer, 636
 in pancreatic cancer, 225

Gender, in melanoma, 728

Gene
 mismatch repair, in gastric cancer, 301-302
 tumor suppressor, in gastric cancer, 301-302, 309-310

Gene delivery
 liposome-mediated, 176-177
 particle-mediated, 175-176

Gene targeting
 barriers to, 189-191
 in cancer therapy, 188-193

Gene therapy
 for benign conditions, 4-5
 for cancer, 4-21
 clinical trials of, 38-39
 direct, 106
 drug resistance, rationale for, 52-54
 genetic immunotoxin for, 148-150
 HSV-TK, 34-36
 indirect, 106
 intracellular antibody for, 150-152
 mosaic theory of, 32-34
 noninfectious gene transfer in, 172-181
 overview of, 1-3
 parvoviral vectors for, 159-168
 systemic administration of, 157
 targeting of, 11-12
 tissue specific promoters in, 154-158

Gene transfer
 antigen, 17
 cationic lipid-mediated, 73-74
 cytokine, 16-17
 efficiency of, 12
 for immunity development, 17
 in situ in vivo, 17-18
 mechanisms of, 10-11
 technologies for, 174-178
 to tumor cells in situ, 18

Genetic abnormality, in pancreatic cancer, 245-246

Genetic engineering, for chemotherapy facilitation, 13-19

Genetic immunotoxin
 for cancer therapy, 148-149, 150
 potential advantages of, 149-150
 recombinant, 149
 selective cytotoxicity of, 149

Genitalia
 melanocytic nevus on, 700
 melanosis of, 698

Genome, instability of, 579-580

Genomic hybridization, comparative, 573

GI 9273, 214-215

GI 9277, 214

GI 9283, 215

GI 9982, 215

Giant melanocytic nevus, melanoma arising in, 706

Glutathione S-transferase, 440

Glutathione S-transferase M1, 541

GM2, 778
Gompertzian kinetics, 488
Gonadotrophin release inhibitors, mechanism of action of, in breast cancer, 496
Goserelin, 497, 502, 520
Granulocyte colony stimulating factor, 54
Granulocyte-macrophage colony stimulating factor, 54
Growth factor(s)
 aberrant expression of, 676
 fibrblast, 673-674
 in gastric cancer, 311-312
 hepatocyte, 311-312
 keratinocyte, 311-312
 mast-stem cell, 673
 melanomas and, 673-681
 signal transduction and, 674-675
GSP, functional classification of, 6

Hydroxyandrostenedione, 519
H-2 blockers, gastric cancer, and, 288
H-ras oncogene, 189-190
 in bladder cancer, 578
 functional classification of, 6
 targeting of, 191
Halo nevus, 697-698
Halstedian paradigm
 definition of, 416
 mastectomy and, 418
 replacement of, 416-418
Hammerhead ribozyme, 166
Haptens, 775
Harvey murine sarcoma virus, 54-55
Helicobacter pylori, gastric cancer, and, 288
Hematopoietic cell
 chemoprotection of, 163-164
 transduction of, with adeno-associated virus vectors, 163-164
Hematopoietic support, with chemotherapy, 487-488
Hematuria
 in clinical evaluation, algorithm for, 554
 for screening, in bladder cancer, 590-593
Hemorrhagic tumor necrosis, 36-38
Hen egg white lysozyme, 167
Hepatocellular cancer, p53 abnormalities in, 67-68
Hepatocyte growth factor, 673-674
 in gastric cancer, 311-312
Hepatogastric ligament, 329
HER-2/neu receptor, 518-519
Hereditary nonpolyposis colorectal cancer, familial pancreatic cancer and, 260
Hereditary syndrome, pancreatic cancer and, 246
Herpes simplex virus thymidine kinase gene, see HSV-TK gene
Heterozygosity, loss of, 573
 in breast cancer, 438
Hexamethylmelamine, as single-agent chemotherapy, in pancreatic cancer, 221
HLA antigen, 17
 HLA-B7, 17, 18
HMB-45, 691
Hoechst 33258, 564-565
Holliday junction, 5

Hoogsteen base pairing, 13
Hormonal therapy, in pancreatic cancer, 224-225
Hospice care
 in pancreatic cancer, 238-239
 referral to, 239
Hot spot codon, 67
Housekeeping gene, characteristics of, 8-9
HST, functional classification of, 6
HSV-TK gene, 14-15, 18, 33, 39-40
 clinical protocols of, 41
 delivery of, 34-36
 as suicide gene, 167-168
 uses of, 40
Human leukocyte antigen, 778
Hybridization
 comparative genomic, 573
 fluorescent in situ, 573
Hydrocodone, in pancreatic cancer, 234
Hydromorphone, for moderate to severe pain, 235
Hyperdiploidy, pancreatic cancer and, 246
Hyperplasia
 atypical ductal, *v* duct carcinoma in situ, 429
 atypical lobular, 428-429
Hyperthermia, in pancreatic cancer, 218
Hypophysectomy
 in breast cancer, 497-498
 mechanism of action of, 496

Idoxifene, in breast cancer, 499
Ifosfamide, 222
 in bladder cancer, 635
 in pancreatic cancer, 221
Ifosfamide, vinblastine, gallium nitrate regimen, in bladder cancer, 640
IL-2, *see* Interleukin-2
Ileal neobladder, 608-609
Immune response
 cell-mediated, generation of, 89-91
 character of, 91-92
Immunization
 current active tumor, strategies for, 136
 elements essential to, 15
 polynucleotide-mediated, 135-147
 advantages of, 144-145
 to CEA, *see* Carcinoembryonic antigen immunization
 DNA constructs for, 141-142
 immune mechanisms in, 139-141
 mechanism of, 139
 RNA constructs for, 142-144
Immunotherapy, in postoperative adjuvant regimens, for gastric cancer, 385
Immunotherapy
 adoptive, 18-19
 with bacillus Calmette-Guerin, in bladder cancer, 599-601
 clinical response in, laboratory correlates with, 757
 gene transfer-based approaches to, 93
 genetic engineering facilitating, 14
 in uveal melanoma, 766
Immunotolerance, 756-757
Indiana pouch, 608

Inducible promoter, 179-180

Industrial carcinogens, pancreatic cancer and, 245

Infiltrating lobular carcinoma, of breast, 432

Institute Curie trial, in breast cancer, 466

Integrins, in tumor cell invasion, 319

Interferon, 221

- adjuvant application of, 737-743
- in bladder cancer, 601-602
- IL-2 plus, in melanoma, 741
- immunomodulation with, 737
- vaccine plus, in melanoma, 741-742

Interferon, dacarbazine, carbustine, cisplatin, tamoxifen, interleukin-2 regimen, in metastatic melanoma, 750

Interferon-alfa, cisplatin, vinblastine, dacarbazine, IL-2 regimen, in metastatic melanoma, 750

Interferon-alfa, dacarbazine, carbustine, cisplatin, tamoxifen regimen, in metastatic melanoma, 750

Interferon-alfa-2, phase I-II trials of, in cutaneous melanoma, 737-738

Interferon-alfa-2A

- high-dose, in resected melanoma, 740
- low-dose
- in resected high-risk melanoma, 740-741
- in resected intermediate-risk melanoma, 741

Interferon-alfa-2B, high-dose, in resected melanoma, 738-739

Interferon-gamma, phase I-II trials of, in cutaneous melanoma, 737-738

Interleukin-2

- interferon plus, in melanoma, 741
- murine, 18-19
- production of, 167

Interleukin-2, cisplatin, vinblastine, dacarbazine, interferon-alfa regimen, in metastatic melanoma, 750

Interleukin-2, dacarbazine, carbustine, cisplatin, tamoxifen, interferon regimen, in metastatic melanoma, 750

Interleukin-2, dacarbazine, cisplatin, tamoxifen regimen, in metastatic melanoma, 750

Interleukin-10, 92

Internal ribosome entry site, 55

Interstitial irradiation, in pancreatic cancer, 216-217

Intestinal metaplasia, 294

- gastric cancer and, 287-288, 292-293

Intrabody

- in cytosol, 151-152
- in nucleus, 151-152
- in secretory pathway, 150-151

Intracellular antibody, for cancer gene therapy, 150-152

Intravesical therapy

- with bacillus Calmette-Guerin, complications of, 601
- in bladder cancer, indications for, 598-599

Irinotecan, 514

Jaundice, in pancreatic cancer, 208-209

Jewett-Strong-Marshall classification, of bladder cancer, 552

Junctional nevus, 695

- above macrophage band, 701

Jurkat T cell line, 114

K-ras, 13, 264

K-sam gene, in gastric cancer, 311-312

Kamino body, 699

Keratinocyte, 656

Keratinocyte growth factor, in gastric cancer, 311-312

KI-67, 565

Ki-67 antigen, in breast cancer, 433

Ki-RAS, functional classification of, 6

Kidney tumor, suppressor gene in, 24

Kinetic model, of breast cancer, 488-489

KIT ligand, 673

Kock pouch, 608-609

Krukenberg tumor, 330

KS3, functional classification of, 6

L-31, in gastric cancer, 312

L-phenylalanine mustard, following radical mastectomy, 419

Laminin receptor, in tumor cell invasion, 319

Laparoscopic ultrasonography, in gastric cancer, 349-350

Laparoscopy

- applications of, 349
- in gastric cancer staging, 347-348
- in pancreatic cancer, 202
- in peritoneal disease, 348
- operative port sites in, 348
- for peritoneal nodule, 349
- for primary antral tumor, 349
- serosal brushing with, for cytology, 349
- surgical technique in, for gastric cancer staging, 348-349

Lentigo

- characteristics of, 693
- solar, 694

Lentigo maligna, 703-704

- epidemiology of, 704
- therapeutic considerations in, 704

Letrazole, 520

Leucovorin, 221, 517

Leukemia, antisense strategies in, 78-87

Leuprolide, 497, 502, 520

Levorphanol, for moderate to severe pain, 235

Lewis-X, 565, 567

Li-Fauneni syndrome, 769

Lichen sclerosis et atrophicus, anogenital nevus associated with, 701

Ligamentum venosum, fissure, 329

Linitis plastica, endoscopic ultrasonography in, 343-344

Liposome(s), for chemotherapy delivery, 517-518

Liposome-mediated gene delivery, 176-177

Lobular carcinoma in situ

- of breast, 446-452
- invasive breast cancer following, 447

Lomastatin, 222

- in combination chemotherapy, for pancreatic cancer, 223-224
- in metastatic melanoma, 745

Losoxantrone, 514

- phase II trials of, 514
- as single agent, in metastatic breast cancer, 523

Loss of heterozygosity, in breast cancer, 438

Lumpectomy

- for duct carcinoma in situ, 422-423
- preoperative chemotherapy plus, 420-422
- radiotherapy following, for duct carcinoma in situ, 423

Luteinizing hormone releasing hormone, in breast cancer, 502

Lymph node(s)
gastric cancer metastases to
 endoscopic ultrasonography for, 339-340
 incidence of, 364
metastases to, polymerase chain reaction detection of, 723
perigastric, numbering scheme for, 304
regional, in breast cancer, 415

Lymph node dissection
elective, in melanoma, 719-724
morbidity following, 355, 356
mortality following, 355, 356
para-aortic, 365
survival following, 364

Lymphadenectomy, selective, evolving role of, 722-723

Lymphocyte(s),
 adoptive immunotherapy with, 18-19
 melanoma antigen recognized tumor infiltrating, 114-115

Lymphoid cell, 114-115

Lymphokine, production of, 91-92

Lymphokine activated killer cell, 18-19

Lymphoma, endoscopic ultrasonography in, 343-344

M344, tumor-associated antigen, 564-565, 567

Magnetic resonance imaging
 in advanced bladder cancer staging, 555-556
 of antral gastric carcinoma, 333
 of gastric cancer, 332-334
 negative-contrast agents for, 332-333
 positive-contrast agents for, 332
 spoiled gradient-recalled acquisition in, 333-334
 technique of, in gastric cancer, 332-333

Major histocompatibility class I molecule, 110

Major histocompatibility complex class I molecule, 754-755

Males
 age-specific gastric cancer incidence in, 285
 gastric cancer incidence in, 283

Malignancy, pre-, in breast cancer, 428-435

Manganese chloride, 332

MAP kinase cascade, 674

Margin(s)
 associated with melanoma, 716
 evaluation of, in breast cancer, 455-456

Marker, serologic, in pancreatic cancer, 202-203

MAS, functional classification of, 6

Mast-stem cell growth factor, 673

Mastectomy
 breast-conserving therapy v, 454
 in current therapy, 422
 for ductal carcinoma in situ, 422-423, 450
 Halsted's radical, history of, 475
 Halstedian principles and, 418
 modified radical, 453-454, 469

Maytansine, as single-agent chemotherapy, in pancreatic cancer, 221

Mechlorethamine, in combination chemotherapy, for breast cancer, 481

Medoxyprogesterone acetate
 in breast cancer, 500
 side effects of, 501

Medullary carcinoma, of breast, 432

Megestrol acetate
 in breast cancer, 500
 side effects of, 501

Megestrol, dacarbazine, carbustine, cisplatin regimen, in metastatic melanoma, 749

Melanocyte, 656
 normal, 673-674

Melanocytic nevus
 giant, melanoma arising in, 706
 as melanoma risk factor, 684-685

Melanoma
 acral lentiginous, 705-706
 active specific immunization in, 773-781
 cyclophosphamide immunopotentiation of, 774-775
 age in, 728
 American Joint Committee Cancer staging of, 729-730
 antigen-supplemented tumor cell in, 775-776
 atypical moles v, 690
 balloon cells in, 691
 biological considerations in, 707-708
 biopsy indications in, 714
 biopsy techniques in, 714-715
 case-control studies of, 650-653
 in cellular blue nevus, 706-707
 choroidal, 764
 clinical simulators of, 694
 cutaneous, classification of, 726
 cytologic features of, 689-690
 defined immunogen vaccines in, 776-778
 dermal cells of, 692
 dermal growth pattern of, 689
 desmoplastic, 691
 desmoplastic neurotrophic, 705
 and dysplastic nevus syndrome susceptibility, chromosome 1 linkage with, 668
 ECOG trial E1684 in, 738-740
 epidermal growth pattern of, 688-689
 European studies of, 653-656
 familial, 729
 familial cutaneous, genes in, 26-27
 follow-up restaging in, 729-730
 gender in, 728
 genetically engineered vaccines in, 778-779
 in giant melanocytic nevus, 706
 growth factors and, 673-681
 hereditary, cohort studies in, 685-686
 histological diagnosis of, 688-692
 histological features of, 688-691
 histological reporting of, 692
 histological simulators of, 694
 histological variants of, 692, 703-707
 human, receptor kinase in, 675-676
 immunologic factors in, 729
 incidence of, 667
 inherited predisposition to, 667-672
 interferon plus IL-2 in, 741
 interferon plus vaccine in, 741-742
 interferon-alfa-2 in, phase I-II trials of, 737-738
 interferon-gamma in, phase I-II trials of, 737-738
 intermediate thickness, elective lymph node dissection in, 719-724

Melanoma (Continued)
 intermittent sun exposure and, 657-658
 study results in, 659
 intraepithelial, 689
 introduction to, 649
 invasive, 691
 iris, 764
 large ciliary body, 764
 with large junctional nests, 689
 lentigo maligna, 703-704
 local surgical treatment goals in, 715-716
 malignant
 diagnosed during pregnancy, 735
 differential diagnosis of, 693-702
 in pregnancy, 734-736
 prior pregnancies and, 735
 prognostic indicators in, 709-710
 radiobiological perspectives of, 760
 radiotherapy in, 759-762
 recurrences in, 710-711
 stage I, risk factors in, 710
 subsequent pregnancy and, 735
 thick, survival in, 711
 margin with relevance to, 716
 metastatic
 betulinic acid in, 745-746
 carmustine in, 745
 chemoimmunotherapy in, 750-751
 cisplatin, tamoxifen regimen in, 748-749
 cisplatin, vinblastine, dacarbazine, IL-2, interferon-alfa regimen in, 750
 combination chemotherapy in, 746-750
 dacarbazine in, 744
 dacarbazine, carmustine, cisplatin, megestrol regimen in, 749
 dacarbazine, carmustine, cisplatin, tamoxifen regimen in, 746-748
 dacarbazine, carmustine, cisplatin, tamoxifen, interleukin-2, interferon regimen in, 750
 dacarbazine, carmustine, cisplatin, tamoxifen, interferon-alfa regimen in, 750
 dacarbazine, cisplatin, tamoxifen regimen in, 749
 dacarbazine, cisplatin, tamoxifen, IL-2 regimen in, 750
 dacarbazine, fotemustine regimen in, 750
 dacarbazine, tamoxifen regimen in, 749
 docetaxol in, 745
 fotemustine in, 745
 lomustine in, 745
 nitrosoureas in, 745
 paclitaxel in, 745
 prognostic factors in, 728-729
 single-agent chemotherapy in, 744-746
 systemic chemotherapy in, 744-753
 tamoxifen in, 744-745
 taxanes in, 745
 temozolomide in, 745
 mucosal lentiginous, 707
 NCCTG trial 83-7052 in, 740
 nodal metastases of, prognostic factors in, 727
 occupational sun exposure and, 658-659
 study results in, 660

Melanoma (Continued)
 other malignant neoplasms *v*, 690-691
 with pagetoid epidermal involvement, 690
 peptides in, 742
 primary
 Clark's staging in, 725
 cytogenetics in, 726
 histologic types of, 726-727
 pathology of, 725-726
 site of, 727
 tumor thickness in, 725-726
 and survival, 726
 primary cutaneous, prognostic factors in, 726
 prognosis in, 725-733
 race in, 728
 random
 case-control studies in, 685
 cohort studies in, 685-686
 recommended follow-up testing in, 731
 recommended staging tests in, 731
 regional lymph nodes in, 727-728
 resected, randomized controlled vaccine trials in, 742
 resected high-risk
 adjuvant therapy of, 738
 interferon-alfa-2A in, 740
 interferon-alfa-2B in, 738-739
 low-dose interferon-alfa-2A in, 740-741
 resected intermediate-risk, low-dose interferon-alfa-2A in, 741
 risk markers for, 682-687
 selective lymphadenectomy in, 722-723
 Sequel intergroup trial E1690 in, 740
 skin color in, 728
 small cells in, 691
 staging in, 725-733
 cost-effectives tests for, 729
 study results in, 656-657
 sun exposure and, 650-666
 surgical management of, 714-718
 by site, 717
 susceptibility to
 chromosome 9P21 and, 668-669
 nevus counts and, genetic analysis of, 668
 targeting to, 155-156
 thickness of, 709
 surgical treatment by, 716-717
 ultraviolet radiation exposure and, 656
 unconventional cutaneous, 709-713
 unusual variants of, 703-708
 US studies of, 650-653
 uveal, *see* Uveal melanoma
 viral oncolysate in, 776
 WHO trial #16 in, 740-741
 whole tumor cell vaccine in, 773-774
 Melanoma antigen recognized tumor infiltrating lymphocyte, 114-115
 Melanoma-associated tumor antigen, 755
 immunotherapy and, 754-758
 Melanosis, of genitalia, 698
 Melanotropin, 673

Melphalan, as single-agent chemotherapy
 in metastatic breast cancer, 523
 in pancreatic cancer, 221

Menetrier's disease
 endoscopic ultrasonography in, 343-344
 gastric cancer and, 294

Menogarol, as single-agent chemotherapy, in pancreatic cancer, 221

MET, functional classification of, 6

Metaplasia
 gastric cancer and, 287-288, 292-293
 intestinal, 294

Metastasis
 in gastric cancer, 316-324
 organ specificity of, prediction of, 441-442
 to lymph nodes, 339-340, 364
 to peritoneum, 364-365

Metastasis-related gene, in gastric cancer, 312

Methadone, for moderate to severe pain, 235

Methotrexate
 escalated, in bladder cancer, 639
 high-dose, in combination chemotherapy, for advanced gastric cancer, 399-401
 in bladder cancer, 634, 638-639
 in breast cancer, 419, 420, 469, 470, 481-482
 in combination chemotherapy, 481
 for bladder cancer, 615, 622
 in combined modality therapy, for bladder cancer, 615
 overview of, 484-485
 postoperative adjuvant, in gastric cancer, 381
 as single agent, in metastatic breast cancer, 523

Methotrexate, cisplatin regimen, in bladder cancer, 636-637

Methotrexate, cisplatin, vinblastine regimen, in bladder cancer, 638

Methotrexate, doxorubicin, cisplatin regimen, intra-arterial, in bladder cancer, 624

Methyl-CCNU, 222
 in combination chemotherapy, 223
 in pancreatic cancer, 221

Methylcholanthrene-induced 101 murine fibrosarcoma, 110

Methylguanine methyltransferase, 48-49
 in drug resistance gene transfer, 56

MGBG, as single-agent chemotherapy, in pancreatic cancer, 221

Micrometastasis, of breast cancer, in bone marrow, 439-440

Microsatellite, 716

Mifepristone, 520

Milan Cancer Institute trial, in breast cancer, 468-471

Miniprobe, 342

Minnesota Multiphasic Personality Inventory, 229

Mitogen-activated protein kinase, 674

Mitomycin
 in combination chemotherapy, 223
 in gastric cancer, 374-376
 in pancreatic cancer, 221
 in postoperative adjuvant regimens, for gastric cancer, 382-383
 postoperative adjuvant, in gastric cancer, 381
 as single-agent chemotherapy, 221
 in metastatic breast cancer, 523

Mitotic figure, counting of, in breast cancer, 432

Mitotic spindle, cytotoxic destruction of, 506-513

Mitoxantrone, 515
 in bladder cancer, 634
 in breast cancer therapy, 468, 469
 in combination chemotherapy, 515
 dose intensity trials of, 515
 single-agent activity of
 in metastatic breast cancer, 523
 in pancreatic cancer, 221

MLM locus, 669
 CDKN2 gene and, 669-670
 expressivity of, 669
 penetrance of, 669

MMP-2, 319-320

MMP-9, 320

Model
 dose response, to sun exposure, 663-665
 kinetic, of breast cancer, 488-489
 molecular, of tumor progression, 683-684
 of tumorigenesis, 580

Monoclonal antibody(ies), 518-519
 in breast cancer, 490
 in pancreatic cancer, 225

Morphine
 for moderate to severe pain, 235
 in pancreatic cancer, 234

Mosaic theory, of gene therapy, 32-34

MRI, see Magnetic resonance imaging

MTS1, 12, 669-670
 tumors associated with, 8

Mucinous carcinoma, of breast, 432

Mucosal lentiginous melanoma, 707

Mucosectomy, 341

Multiple drug resistance, 14

Multiple drug resistance gene-1, 47-48

Multiple drug resistance gene-2, 47

Multiple drug resistance gene-3, 47

Multiple drug resistance protein, 51
 in breast cancer, 440

MYC, functional classification of, 6

Myosin, in tumor cell invasion, 319

N-acetylation, 541

N-acetyltransferase 2, 540

N-MYC, functional classification of, 6

N-nitroso compounds, gastric cancer and, 284-286

N-RAS, functional classification of, 6

2-Naphthylamine, exposure to, bladder cancer risk of, 537

Narcotic analgesics, in pancreatic cancer, 234-236

National Cancer Institute trial, in breast cancer, 467

National Surgical Adjuvant Breast and Bowel Project, 415-416

National Surgical Adjuvant Breast Project, 467

Nausea, following opioids, 236-237

Negative selectable marker, additional, 39-40
 classes of, 32

Neoadjuvant therapy
 in locally advanced gastric cancer, 403
 in gastric cancer, 379-389

NEU oncogene, overexpression of, in breast cancer, 438

NEU-erb-B2, functional classification of, 6

Neurofibromatosis type I, 769

Neurovascular bundle, 607

Neutron irradiation, in pancreatic cancer, 216

Nevus(i)

- acquired, 695
- on acral skin, 701
- anogenital, associated with lichen sclerosus et atrophicus, 701
- atypical, 695-696
- blue, 696
- cellular blue, melanoma in, 706-707
- clonal, 699-700
- combined, 699-700
- common acquired, 684
- congenital, 693-695
- deep penetrating, 700
- dysplastic, *see* Dysplastic nevi
- excisional biopsy of, 715
- giant melanocytic, melanoma arising in, 706
- halo, 697-698
- junctional, above macrophage band, 701
- melanocytic
 - compound, 60
 - on genitalia, 700
 - intradermal, 690
 - junctional, 689
 - as melanoma risk factor, 684-685
 - as melanoma risk factor, 684-685
 - on palms, 700-701
 - persistent, 697-698
 - recurrent, 697-698
 - on soles, 700-701
 - Spitz's, 698-699
- NF-1, tumors associated with, 8
- NF-2, tumors associated with, 8
- Nitrites, gastric cancer and, 285-287
- Nitrosourea agents
 - in metastatic melanoma, 745
 - in pancreatic cancer, 222
 - in postoperative adjuvant regimens, for gastric cancer, 382
- Nm23, in gastric cancer, 312
- Nonsteroidal anti-inflammatory drugs, in pancreatic cancer, 234
- Norethisterone, in breast cancer, 500
- Nottingham Prognostic Index, 442
- NSABP B-04 trial, 417
- NSABP B-06 trial, 417, 423
- NSABP B-13 trial, 420
- NSABP B-14 trial, 424
- NSABP B-17 trial, 423
- NSABP B-18 trial, 420-422
- NSABP B-22 trial, 485
- NSABP B-24 trial, 451
- NSABP P-1 trial, 424
- Nuclear pleomorphism, 692
- Nuclear pseudoinclusion, 692
- Nucleosome, 190
- Nucleotide excision repair, 50-51
- O⁶-alkylguanine DNA alkyltransferase, 48
- Octreotide, 224-225
- Ocular melanocytosis, 768-769
 - with episcleral pigmentation, 769
- OK-432, in gastric cancer, 373-374

Oligodeoxynucleotide(s)

- antisense, ex vivo treatment with, 83-84
- biodistribution of, 81-82
- characteristics of, 78-79
- chemistry of, 85
- delivery strategies for, 85
- oncogene-targeted antisense, 83-84
- pharmacokinetics of, 81-82
- safety studies of, 82-83
- systemic treatment with, 84-85

Oligonucleotide, RNA-DNA chimeric, 189

Onapristone, 521

Oncogene

- activation of, 6-7, 28
- definition of, 27-28
- functional classification of, 6
- history of, 5-7
- in gastric cancer, 311-312
- in pancreatic cancer, 263-264
- mechanism of activation of, 7
- viral, 29

Oncogenesis

- in colorectal cancer, 9-10
- mechanisms of, 9-10

Oncotropic vector, 168

Oophorectomy

- radiation-induced, 495-497
- surgical, 495

Opioid analgesic, in pancreatic cancer, 234-236

Orbital exenteration, in uveal melanoma, 766

Ovarian cancer, targeting to, 156-157

Overexpression, oncogene activation by, 28-29

Oxycodone

- for moderate to severe pain, 235
- in pancreatic cancer, 234

Oxygen enhancement ratio, 216

P-cadherin, in gastric cancer, 309-310

P-glycoprotein, 440, 47-48

P-gp, in drug resistance gene transfer, 54-55

P103, 675

P130, 675

P15, 310-311

P16, 310-311, 684

P21, 310-311

p53, 565, 675

- adenovirus-mediated delivery of, preclinical studies with, 70-71
- alterations of, 579-580
- in bladder cancer, 576
- in breast cancer, 438
- cationic lipid complex with, 74
- in colorectal cancer, 66-67
- delivery of, adenoviral vectors for, 68-70
- dominant-negative hypothesis of, 68
- gene therapy with, *in vivo*, 66-77
- in hepatocellular cancer, 67-68
- as prognostic factor, 429, 433
- rAd-, strategy for, 71-72
- role of, model of, 572
- tumors associated with, 8

p53, 565, 675 (Continued)
in uveal melanoma, 770
vector systems for, 72-74
wild-type
 biochemical properties of, 66
 cellular function of, 66

Paclitaxel, 506, 507-510
 in bladder cancer, 635
 in breast cancer, 489
 doxorubicin plus, 509-510
 in metastatic breast cancer, 508
 in metastatic melanoma, 745
 in pancreatic cancer, 225
 as single agent, in metastatic breast cancer, 523

PAI-1, 320-321

Pain
 assessment of, 232-233
 moderate to severe, narcotic agents for, 235
 in pancreatic cancer, 230-238
 patient-controlled analgesia for, 235-236
 pharmacologic treatment of, 233-237
 syndromes of, 230-232
 treatment of, 232-233

PALA, *see* Phosphonacetyl-L aspartic acid

Palliative care
 in pancreatic cancer, 229-240
 radiotherapy as, 237

Palm, nevus on, 700-701

Pamidronate, 522

Pancreas, adenocarcinoma of, 220-228

Pancreatectomy
 regional, 206
 total, survival following, 205-206

Pancreatic cancer
 biologic therapy in, 225
 biopsy techniques in, 202
 chemical exposure and, 245
 chemotherapy in, 267-268
 chronic pancreatitis and, 247
 cigarette smoking and, 244-245
 combination chemotherapy in, 222-224
 common combination chemotherapy in, 223
 CT in, 265
 cytarabine in, 225
 depressive disorders in, 229-230
 diabetes and, 246-247
 diagnosis of, 201-203
 dietary carcinogens and, 243-244
 differential diagnosis of, 260
 docetaxel in, 225
 endoscopic evaluation in, 201-202
 endoscopic retrograde cholangiopancreatography in, 265-266
 endoscopic ultrasonography in, 202, 266-267
 epidemiology in, 241-250
 external particle therapy in, 216
 familial, *see* Familial pancreatic cancer
 gemcitabine in, 225
 high-risk screening in, diagnostic approach to, 267
 hormonal therapy in, 224-225
 hospice care in, 238-239
 hyperthermia in, 218

Pancreatic cancer (Continued)
 incidence of, 241-243
 industrial carcinogens and, 245
 inherited predisposition to, 245-246
 interstitial irradiation in, 216-217
 intraoperative radiotherapy in, 217-218
 introduction to, 199
 laparoscopy in, 202
 locally unresectable, treatment of, 214
 markers in, 202-203
 molecular biology of, 262-264
 monoclonal antibodies in, 225
 morbidity in, 207-208
 mortality in, 207-208
 neutron radiotherapy in, 216
 noninvasive diagnostic tests in, 201
 nonoperative palliative approaches in, 209
 oncogenes in, 263-264
 operative management of, 203-207
 operative survival in, 207-208
 paclitaxel in, 225
 pain assessment in, 232-233
 pain in, 230-238
 pain syndromes in, 230-232
 pain treatment in, 232-233
 palliative care in, 229-240
 papillary duct hyperplasia and, 247
 pathology of, 262-264
 PET in, 266
 pharmacologic pain treatment in, 233-237
 predisposing medical conditions to, 246-247
 prosthetic stents in, 209
 radiation and, 245
 radiosensitizers in, 216
 radiotherapy in, 213-219
 risk factors in, 241-250
 screening in, 264
 serologic tests in, 265
 single-agent chemotherapy in, 221
 staging in, 201-203
 surgical management of, 200-212
 surgical palliation in, 208-209
 surgical therapy in, 267
 terminal care in, 238-239
 transcutaneous ultrasound in, 265

Pancreatico-gastrostomy, 205

Pancreaticoduodenal resection, 200

Pancreaticoduodenectomy, 203
 extended, 206
 five-year survival following, 207
 radical, 206

Pancreaticojejunal anastomosis, 205

Pancreatitis
 chronic, pancreatic cancer and, 247
 hereditary, 255-257

Papanicolaou cytology, in transitional cell carcinoma, 564-565

Papillary duct hyperplasia, pancreatic cancer and, 247

Partial lamellar sclerouectomy, in uveal melanoma, 765

Parvovirus
 autonomous, 161-162
 biology of, 159

Parvovirus (*Continued*)
 vectors, to gene therapy, 162-163

Passenger gene, 10-11

Patey operation, 469

Peptide(s)
 antigenic, 778
 melanoma-associated antigenic, 756

Perflubron, 332

Perfluorooctylbromide, 332

PET, *see* Positron emission tomography

Phase I-II trial
 of interferon-alfa-2, in cutaneous melanoma, 737-738
 of interferon-gamma, in cutaneous melanoma, 737

Phosphonacetyl-L aspartic acid, 220-221

Photocoagulation, laser, in uveal melanoma, 765

Photodynamic therapy, photofrin-mediated, in bladder cancer, 602

Pirarubicin, in bladder cancer, 634

Pirritexim, in bladder cancer, 636

Piroxantrone, 514

Plasmid, episomal, 181

Plasmid vector, replicating, 180-182

Plasminogen activator inhibitor
 in breast cancer, 439
 in tumor cell invasion, 320

Plasminogen activators, urokinase-type, in tumor cell invasion, 319

Pleomorphic lobular carcinoma, of breast, 432

Point mutation, oncogene activation by, 28

Polymerase chain reaction, 438
 technique with, 565

Polyps, gastric, gastric cancer and, 293-294

Positron emission tomography, in pancreatic cancer, 266

Practice guidelines, for pain, 232

PRAD-1, in breast cancer, 438

PRb
 alterations of, in bladder cancer, 576, 578-579
 role of, model of, 572

Prednisone, in combination chemotherapy, for breast cancer, 481

Pregnancy
 in malignant melanoma, 734-736
 prior to malignant melanoma, 735

Premalignancy, as breast cancer risk, 428-429

Probe, ultrasonic, 342

Procarbazine, in combination chemotherapy, for breast cancer, 481

Progesterins
 in breast cancer, 500
 mechanism of action of, 496

Prognostic factor(s)
 as adjuvant therapy guidelines, in breast cancer, 442
 in bladder cancer, 629
 in breast cancer, 429, 433, 437
 critical evaluation of, 436-445
 micrometastases as, 436-440
 molecular, 437-440
 morphologic, in breast cancer, 436-440

Prognostic marker(s)
 of biological behavior, 441
 development of, challenges in, 442

Proliferating cell nuclear antigen, 565

Promoter
 inducible, 179-180
 tissue specific, 178-179

Prostatic cancer, targeting to, 157

Protein-bound beta-D-glucan, in gastric cancer, 373-374

Proteinase inhibitor, in tumor cell invasion, 319

Proteinases, in tumor cell invasion, 319

Proteolytic enzyme, in breast cancer, 439

Protocol G9173, 214

Protooncogene, definition of, 6

PS2 protein, in breast cancer, 441

Pseudotumor, gastric, 329

PTP gamma gene, intron-exon structure of, 25-26

Pump-1, 320-321

Putative metalloproteinase, 321

Quadrantectomy, 458

Quality of life, following gastric resection, 365-366

Quantitative fluorescence image analysis, 565

Race
 gastric cancer incidence by, 282
 in bladder cancer, 537
 in melanoma, 728

Radiation
 pancreatic cancer and, 245
 surgery plus, for ductal carcinoma in situ, 449-451

Radiography
 in advanced gastric cancer, 326-327
 in early gastric cancer, 325-326
 of gastric ulcers, 326
 in cirrhotic gastric cancer, 326-327
 upper gastrointestinal, in gastric cancer detection, 325

Radiosensitizer, in pancreatic cancer, 216

Radiotherapy
 in advanced gastric cancer, 402
 adjuvant, results of, 392-393
 adjuvant therapy plus, in pancreatic cancer, 214
 bladder preservation and, 626-627
 chemotherapy sequencing and, for invasive breast cancer, 460
 clinical perspectives of, in malignant melanoma, 760-761
 conventional, with or without chemotherapy, 215-216
 external beam, 392
 following lumpectomy, for duct carcinoma in situ, 423
 following noncurative surgery, 393-394
 in gastric cancer, 390-396
 Gastrointestinal Study Group Trials of, 213-215
 historical perspectives in, for malignant melanoma, 759-760
 idealized treatment fields for, 392
 interstitial, 216-217
 intraoperative, 216-218, 394-395
 in malignant melanoma, 759-762
 multiple field technique in, 390
 neutron, 216
 palliative
 in gastric cancer, 395
 in pancreatic cancer, 237
 in pancreatic cancer, 213-219
 postoperative adjuvant, 383-384
 in gastric cancer, 381
 preoperative, 216

Radiotherapy (Continued)
radical, cost of, 629
rationale for, in gastric cancer, 390
in resected tumors, 215
surgery plus, relative timing of, 484
technical aspects of, 390-391
three dimensional treatment planning with, 390-391
toxicity of, 391-392
in unresectable disease, 215-218
in uveal melanoma, 765

RAF, functional classification of, 6

RAS oncogene
in bladder cancer, 578
in uveal melanoma, 770

RAS peptide, mutant, immunogenicity of, 123-125

RAS p21 oncogene
amino acid substitutions and, 121
point-mutated, as immunotherapy targets, 121
products of, 121-126
tumorigenesis and, 118-120

Razoxane, as single-agent chemotherapy, in pancreatic cancer, 221

RB, alterations of, in bladder cancer, 576

RBI, tumors associated with, 8

Renal cell cancer, chromosome 3p depletions in, 24-25

Replication error, in gastric cancer, 301-302, 307-309

Representational difference analysis, 263

Research
in breast cancer, 414-427
in 1960s, 414-416

Respiratory depression, following opioids, 237

RET, functional classification of, 6

Retinoblastoma, 675
hereditary, 575

Retrograde cholangiopancreatography, endoscopy with, in pancreatic cancer, 201-202

Retroviral vector, for p53, 73

Retrovirus, definiton of, 6

Ribosomal S kinase, 674

Ribozyme, 165-166

Rous sarcoma virus, 6

Royal Marsden trial, in breast cancer, 466-467

Rubber tire industry, bladder cancer risk of, 537

S phase determination, in breast cancer, 432-433

S-100 protein, 691

Salt, gastric cancer and, 287

Scatter factor, 673-674

Schistosoma haematobium, 542

Schistosomiasis infection, as bladder cancer risk factor, 539-540

Schistosomiasis haematobium, 542

Scirrhous carcinoma, endoscopic ultrasonography in, 343-344

Screening
biomarkers for, in bladder cancer, 594
cytology for, in bladder cancer, 593-594
flow cytometry for, in bladder cancer, 593-594
for chronic diseases, principles of, 585-587
hematuria for, in bladder cancer, 590-593
in high-risk populations
for bladder cancer, 594-595
for pancreatic cancer, 267

Semustine, 222

Senescence, cellular, 577-579

Serologic test, in pancreatic cancer, 265

Sex, gastric cancer incidence by, 282, 283

Sexual function, following radical cystectomy, 607

Signal 2, 757

Single-strand confirmation polymorphism, 438

SK-GT-5, 323

Skin, sensitivity of, to ultraviolet radiation, 656, 663

Skin color, in melanoma, 728

Skipper's hypothesis, 421

Sloan-Kettering Gastric Tumor cell lines, 316-324

Smoking, cigarette, 589
bladder cancer risk of, 537-538
gastric cancer and, 288
pancreatic cancer and, 243-244

Solar keratosis, melanocytic proliferation in, 701

Solar lentigines, melanocytic proliferation in, 701

Solar lentigo, 694
melanocytic proliferation in, 701

Sole, nevus on, 700-701

Somatostatin, 224-225

Spindle poisons, 506-513

Spirogemanium, as single-agent chemotherapy, 221

Spironolactone, in combination chemotherapy, 223

Spitz's nevus, 698-699

Splanchnic nerve block, 238

Spoiled gradient-recalled acquisition, in steady state, 333

Steel factor, 673

Stem cell, 115
with chemotherapy, 487-488

Stem cell factor, 55

Stem cell growth factor, 673

Stomach
cancer of, see Gastric cancer
cell necrosis in, 296
epithelial dysplasia of, 295
five-layer wall structure of, endoscopic ultrasonography for, 337
lymphatic channels from, 363
polyps of, cancer and, 293-294
postsurgical, cancer and, 294-295
regional lymph node of, by N classification, 363
surgery of, see Gastric resection
ulcer of, cancer and, 293
wall of, laparoscopic wedge resection of, 366

Streptozocin, 222
in combination chemotherapy, 223
as single-agent chemotherapy, 221

Strip biopsy, 341

Stromelysin(s), in tumor cell invasion, 319-321

Stromelysin-2, 321

Strontium, 522-523

Suicide gene, 14, 167-168
in situ use of, 31-45
therapy with, benefits of, 40
types of, 33

Sun exposure
dose response models to, 663-665
intermittent

Sun exposure (Continued)
 melanoma and, 657-658
 relative risks for, 658

intermittent *v* occupational, 659-660
 relative risks for, 661
 melanoma and, 650-666

occupational, 658-659
 relative risks for, 660
 study results in, 660

total, 660-662
 relative risks for, 661
 study results in, 662

Sunburn
 history of, 662-663
 relative risks for, 662
 study results in, 664

Superoxide dismutase, 51-52

Suppressor gene
 identification of, 23
 in kidney tumors, 24
 mutations in, 25-26

Surgery
 in bladder cancer, 605-613
 in breast cancer, 420
 breast-conserving, techniques of, 458
 for ductal carcinoma in situ, 449-451
 for gastric cancer, in US, 352-359
 gastric cancer recurrence following, 342
 margin evaluation following, 455-456
 noncurative, in gastric cancer, radiotherapy following, 393-394
 optimal timing of, 459-460
 palliative, 208-209
 in pancreatic cancer, 200-212, 267
 radiation plus, for ductal carcinoma in situ, 449-451
 radiotherapy plus, relative timing of, 484
 for urinary tract reconstruction, 606-610
 wide excision, for invasive breast cancer, 460

Sweeteners, artificial, bladder cancer risk of, 539

T cell
 activation of, 90, 754-755
 antitumor, genetic manipulation of, 111-114
 cytotoxic, generation of, 15
 therapy with, genetic approaches to, 109

T cell receptor, 120-121

T cell response, 89-91

T effector cell
 cytokine gene transfection of, 112-113
 genetic engineering of, 114-115
 modification of, with signal transduction genes, 113
 redirection of, with chimeric receptor gene, 113-114

T lymphocyte, 15, 17
 cytotoxic, tumor cell interaction with, 15, 17

Tamoxifen, 224-225, 419, 521 (Continued)
 mechanism of action of, 496
 in metastatic melanoma, 744-745
 optimal duration of, 479
 overview of, 478-481
 in postoperative adjuvant regimens, for gastric cancer, 385
 side effects of, 500

Tamoxifen, cisplatin regimen, in metastatic melanoma, 748-749

Tamoxifen, dacarbazine regimen, in metastatic melanoma, 749

Tamoxifen, dacarbazine, carmustine, cisplatin regimen, in metastatic melanoma, 746-748

Tamoxifen, dacarbazine, carmustine, cisplatin, interferon-alfa regimen, in metastatic melanoma, 750

Tamoxifen, dacarbazine, carmustine, cisplatin, interleukin-2, interferon regimen, in metastatic melanoma, 750

Tamoxifen, dacarbazine, cisplatin regimen, in metastatic melanoma, 749

Tamoxifen, dacarbazine, cisplatin, IL-2 regimen, in metastatic melanoma, 750

Taxane(s), 422
 in metastatic melanoma, 745

Tegafur-uracil
 in gastric cancer, 374-376
 postoperative adjuvant, 381

Telomerase
 alterations in, 579
 in gastric cancer, 308

Telomere, alterations in, 579

Temozolomide, in metastatic melanoma, 745

Teniposide, in bladder cancer, 635

Terminal care, in pancreatic cancer, 238-239

Testosterone-dihydrotestosterone ratio, 203

Textile dye industry, bladder cancer risk of, 537

TH1, definition of, 91

TH2, definition of, 91

Thiotepa, vinblastine, doxorubicin, fluoxymesterone regimen, in breast cancer, 486

Thirty-one-kd lactoside-binding lectin, in gastric cancer, 312

TIMP-1, 320

TIMP-2, 320

Tissue inhibitor metalloproteinase, in tumor cell invasion, 320

Tissue specific promoter, 178-179
 in gene therapy, 154-158

TLC D-99, 517

TNM staging, of gastric cancer, 300

Tobacco, familial pancreatic cancer and, 252

Topoisomerase I, 513

Topoisomerase II, 513-514

Topotecan, 514
 as single-agent chemotherapy, in metastatic breast cancer, 523

Toremifene, 521
 in breast cancer, 499

TP53
 alterations of, in bladder cancer, 576
 mutations of, spectrum of, 577

Transdominant molecule, delivery of, 164-166

Transduction, mechanism of, 10

Transfection, mechanism of, 10

Transitional cell carcinoma, 542, 547-548
 biomarkers for, 563-564

Transitional cell carcinoma, 542, 547-548 (Continued)
 clinical evaluation in, algorithm for, 554
 in situ, 551
 nonpapillary flat, 549-551
 papillary, 550

Translocation, oncogene activation by, 29

Transpupillary thermotherapy, in uveal melanoma, 765

Transurethral resection of bladder tumor, 552-555
 bladder preservation and, 625-627

Trimeretrexate, 516
 in bladder cancer, 636

Triptorelin, 497, 502

TRK, functional classification of, 6

Tubular carcinoma, of breast, 431-432

Tumor
 gene-modified, for antitumor T cell, 109-111
 induced suppressive activity, 92
 progression of, molecular models of, 683-684
 specific transplantation antigen, 90

Tumor antigen, production of, 15-16

Tumor cell
 cytotoxic T lymphocyte interaction with, 15, 17
 genetic alterations in, detection of, 22-30

Tumor doubling time, in gastric cancer, 301

Tumor infiltrating lymphocyte, 18-19
 from gene-modified tumor, 109-110
 marking study, 111-112

Tumor marker, prognostic, in breast cancer, 421-422

Tumor suppressor gene, 575-577
 associated with bladder cancer, 542
 characteristics of, 7-8
 in gastric cancer, 301-302, 309-310
 role of, in bladder cancer, 575
 tumors associated with, 8

Tumor vaccine
 animal studies of, 102-104
 animal study conclusions in, 104
 DNA, 105
 ex *vivo* *in vivo* approach to, 105
 gene-modified, lymph node cells sensitized with, 110-111
 in humans, 104-105
 immunotherapy with, 101-107
 rationale for, 101-102
 targets for, mutant ras epitopes as, 118-134
 therapeutic benefit of, 103

Tumorectomy, 458

Tumorigenesis, genetic pathways in, model of, 580

Two-hit hypothesis, 7-8

Tyrosinase-related protein 1 gene, 154

TZT, as single-agent chemotherapy, in pancreatic cancer, 221

Ulcer
 benign v malignant gastric, radiographic findings in, 326-327
 gastric, gastric cancer and, 293
 malignant gastric, radiography of, 328

Ultrasonic probes, 342

Ultrasoundography
 in advanced bladder cancer staging, 555-556
 endoscopic, 202
 in gastric cancer, 336-346
 laparoscopic, 349-350

Ultrasoundography (Continued)
 in pancreatic cancer, 201, 266-267
 transcutaneous, 265

Ultraviolet radiation
 exposure to, and melanoma, 656
 skin sensitivity to, 663

Uracil-tegafur
 in gastric cancer, 374-376
 postoperative adjuvant, in gastric cancer, 381

Ureterosigmoidostomy, 607

Urinary bladder
 papillary urothelial neoplasms of, 548-549
 preservation of
 concerns regarding, 618-619
 goals of, 614
 neoadjuvant chemotherapy and, 625
 partial cystectomy and, 625
 patient selection for, 614-615
 radiation therapy and, 626-627
 strategies for, 610-612
 transurethral resection and, 625-627

primary tumors of
 classification of, 548
 pathology of, 547-548

transitional cell carcinoma of, surgical therapy for, 605-613

wall of, 547

Urinary tract, reconstruction of, 606-610

Uroepithelial cell, transformation of, 574

Urokinase-type plasminogen activator, in breast cancer, 439

Urothelial tumor, diagnosis of, cytology role in, 560

Urothelium, 546

Uveal melanoma
 bilateral, 769
 chemotherapy in, 766
 classification of, 769-770
 clinical features of, 763
 combined modality therapy in, 766
 conditions predisposing to, 768
 cyclin-dependent kinase-4 inhibitor gene in, 770
 cytogenetic studies in, 770
 diagnostic approaches to, 763
 enucleation in, 765-766
 familial, 768
 genetic aspects of, 768-772
 germline mutations in, 770
 immunotherapy in, 766
 laser photoocoagulation in, 765
 local resection in, 765
 management of, 763-764
 molecular genetic studies in, 770
 observation in, 764-765
 orbital exenteration in, 766
 p53 in, 770
 primary, proposed genetic classification for, 770
 prognosis in, 766
 radiotherapy in, 765
 ras oncogene in, 770
 transgenic models in, 770
 transpupillary thermotherapy in, 765
 typical kindred with, 769
 in young patients, 769

Vaccination, elements essential to, 15

Vaccine

- genetically engineered for cancer, 778-779
- interferon plus, in melanoma, 741-742
- recombinant virus, 16
- tumor, *see* Tumor vaccine
- whole tumor cell, 773-774

Vaccinia virus, 16

- infests with, 95

Vaccinia virus vector, *in situ* cytokine gene transfer with, 88-100

Vector

- development of, 159
- episomal, replication-competent, 181
- infectious, viral-based, 172-173
- oncotropic, 168
- plasmid, replicating, 180-182
- plasmid expression, 178-182
- plasmid-based, gene transfer technologies for, 174-178
- standard plasma, 181

Vegetables, gastric cancer and, 287

VHL, tumors associated with, 8

Vinblastine

- in bladder cancer, 634
- in combination chemotherapy, for bladder cancer, 622

Vinblastine, cisplatin, dacarbazine, IL-2, interferon-alfa regimen, in metastatic melanoma, 750

Vinblastine, cisplatin, methotrexate regimen, in bladder cancer, 638

Vinblastine, doxorubicin, thiotepa, fluoxymesterone regimen, in breast cancer, 486

Vinblastine, ifosfamide, gallium nitrate regimen, in bladder cancer, 640

Vincristine

- in bladder cancer, 634-635

Vincristine (*Continued*)

- in combination chemotherapy
- for bladder cancer, 615
- for breast cancer, 481
- in combined modality therapy, for bladder cancer, 615
- as single agent, in metastatic breast cancer, 523

Vinorelbine, 506-507, 511-513

- in bladder cancer, 635
- in breast cancer, 468, 489
- in combination chemotherapy, 513
- melphalan *v*, 513
- phase II trials of, 512
- as single agent, in metastatic breast cancer, 523

Viral gene, as oncogene, 29

Viral oncolysate, in melanoma, 776

Viral xenogenization, 775

Vomiting

- following opioids, 236-237
- in pancreatic cancer, 208-209

Vorozole, 520

VZV-TK, 33

Whipple procedure, 200

- pylorus-preserving modification of, 205
- standard, 204

World Health Organization classification, of gastric cancer, 298

WT-1, tumors associated with, 8

Xanthine-guanine phosphoribosyltransferase, 33

Xenogenization, viral, 775

Xeroderma pigmentosum, 50

XGPRT, 33

Yagoda, Alan, *in memorium*, 535

